Baidu
map

Biomed Mater:3D打印支架偶联BMP-2衍生肽可增强成骨作用

2020-10-03 MedSci原创 MedSci原创

三维(3D)打印技术为定制骨支架的外部形状和内部结构开辟了新的视角。在这项研究中,研究人员将一种源自骨形态发生蛋白2的低聚肽(SSVPT,Ser-Ser-Val-Pro-Thr)与多巴胺涂层共轭在3D

三维(3D)打印技术为定制骨支架的外部形状和内部结构开辟了新的视角。在这项研究中,研究人员将一种源自骨形态发生蛋白2的低聚肽(SSVPT,Ser-Ser-Val-Pro-Thr)与多巴胺涂层共轭在3D打印的聚乳酸(PLA)支架上,以增强成骨作用。

体外细胞实验表明,该支架对大鼠骨髓间充质干细胞(MSCs)的粘附和增殖具有高度的骨传导作用。此外,RT-PCR分析显示,该支架能够促进成骨相关基因的表达,如碱性磷酸酶(ALP)、Runt相关转录因子2(RUNX2)、骨钙素(OCN)和骨松素(OPN)等。大鼠颅骨缺损模型的显微CT三维重建图像显示,骨再生模式从一侧边缘向植入制备的生物多肽水凝胶的区域中心发生,表明骨再生速度明显加快。

 

综上所述,这项工作将为进一步探索生物活性支架的应用潜力提供基础。

 

原始出处:

 

Xiashiyao ZhangQi Lou,et al., Immobilization of BMP-2-derived peptides on 3D-printed porous scaffolds for enhanced osteogenesis. Biomed Mater. 2019 Nov 15;15(1):015002. doi: 10.1088/1748-605X/ab4c78.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1919140, encodeId=a61b191914020, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 25 03:26:52 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634097, encodeId=6f4f163409e13, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Mon Mar 22 10:26:52 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642680, encodeId=6841164268040, content=<a href='/topic/show?id=814c35e6e2' target=_blank style='color:#2F92EE;'>#BMP-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3576, encryptionId=814c35e6e2, topicName=BMP-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=120c22999408, createdName=12498f17m73暂无昵称, createdTime=Mon Mar 29 00:26:52 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336160, encodeId=ec8d1336160f0, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352256, encodeId=0c22135225682, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610736, encodeId=933f1610e3684, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=)]
    2020-11-25 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1919140, encodeId=a61b191914020, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 25 03:26:52 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634097, encodeId=6f4f163409e13, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Mon Mar 22 10:26:52 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642680, encodeId=6841164268040, content=<a href='/topic/show?id=814c35e6e2' target=_blank style='color:#2F92EE;'>#BMP-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3576, encryptionId=814c35e6e2, topicName=BMP-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=120c22999408, createdName=12498f17m73暂无昵称, createdTime=Mon Mar 29 00:26:52 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336160, encodeId=ec8d1336160f0, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352256, encodeId=0c22135225682, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610736, encodeId=933f1610e3684, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=)]
    2021-03-22 HNYYM
  3. [GetPortalCommentsPageByObjectIdResponse(id=1919140, encodeId=a61b191914020, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 25 03:26:52 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634097, encodeId=6f4f163409e13, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Mon Mar 22 10:26:52 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642680, encodeId=6841164268040, content=<a href='/topic/show?id=814c35e6e2' target=_blank style='color:#2F92EE;'>#BMP-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3576, encryptionId=814c35e6e2, topicName=BMP-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=120c22999408, createdName=12498f17m73暂无昵称, createdTime=Mon Mar 29 00:26:52 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336160, encodeId=ec8d1336160f0, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352256, encodeId=0c22135225682, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610736, encodeId=933f1610e3684, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1919140, encodeId=a61b191914020, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 25 03:26:52 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634097, encodeId=6f4f163409e13, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Mon Mar 22 10:26:52 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642680, encodeId=6841164268040, content=<a href='/topic/show?id=814c35e6e2' target=_blank style='color:#2F92EE;'>#BMP-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3576, encryptionId=814c35e6e2, topicName=BMP-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=120c22999408, createdName=12498f17m73暂无昵称, createdTime=Mon Mar 29 00:26:52 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336160, encodeId=ec8d1336160f0, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352256, encodeId=0c22135225682, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610736, encodeId=933f1610e3684, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1919140, encodeId=a61b191914020, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 25 03:26:52 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634097, encodeId=6f4f163409e13, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Mon Mar 22 10:26:52 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642680, encodeId=6841164268040, content=<a href='/topic/show?id=814c35e6e2' target=_blank style='color:#2F92EE;'>#BMP-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3576, encryptionId=814c35e6e2, topicName=BMP-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=120c22999408, createdName=12498f17m73暂无昵称, createdTime=Mon Mar 29 00:26:52 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336160, encodeId=ec8d1336160f0, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352256, encodeId=0c22135225682, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610736, encodeId=933f1610e3684, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=)]
    2020-10-05 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=1919140, encodeId=a61b191914020, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Nov 25 03:26:52 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634097, encodeId=6f4f163409e13, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Mon Mar 22 10:26:52 CST 2021, time=2021-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642680, encodeId=6841164268040, content=<a href='/topic/show?id=814c35e6e2' target=_blank style='color:#2F92EE;'>#BMP-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3576, encryptionId=814c35e6e2, topicName=BMP-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=120c22999408, createdName=12498f17m73暂无昵称, createdTime=Mon Mar 29 00:26:52 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336160, encodeId=ec8d1336160f0, content=<a href='/topic/show?id=792612047e' target=_blank style='color:#2F92EE;'>#3D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1204, encryptionId=792612047e, topicName=3D)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/pSGl6CJeZ2PzWxdhCtrvv4U9Q281RV8e0AKmlB5ib93DibbiaRyOzmkCdz5F04cbfX5RGOpG4dOXvuQW1fumibVeBg/132, createdBy=fc342500110, createdName=ms9833124466084992, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352256, encodeId=0c22135225682, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610736, encodeId=933f1610e3684, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 05 12:26:52 CST 2020, time=2020-10-05, status=1, ipAttribution=)]

相关资讯

Neuroradiology:取栓后血管成形术和/或支架对ICAS的价值

急性大血管闭塞性(emergent large vessel occlusion,ELVO)急性缺血性卒中是一种危急和致死性疾病。最近发表的随机对照试验显示支架取栓血管内治疗对前循环 ELVO 急性缺血性卒中是有效和安全的。

JACC:ST段抬高型心梗患者应该选哪种冠脉支架?

目前,对于接受经皮冠脉介入治疗(PCI)的ST段抬高型心梗(STEMI)患者,尚无特异有效的药物洗脱支架(DES)被证实优于其他支架。本次荟萃分析研究的目的旨在比较和评估不同冠脉支架在STEMI患者中的安全性和有效性。 本研究回顾分析了来自15个随访时间超过12个月临床研究的10979名PCI患者(男性占77.3%,平均年龄为60.7岁),主要终点事件是心源性死亡、再梗死和靶血管血运重建的复

JACC:冠脉介入术后晚期支架相关不良事件的研究

大部分的经皮冠脉介入治疗(PCI)术后支架相关主要不良心血管事件(MACE)是发生在术后1年内,晚期(>1年)的支架相关不良事件尚未阐明。本研究的目的旨在评估晚期支架相关MACE。本研究纳入分析了25032名接受PCI治疗的患者,其中有3718名接受的是裸金属支架(BMS),7934名接受的是一代药物洗脱支架(DES1),13380名接受的是二代药物洗脱支架(DES2)。MACE在术后1年内的发生

JACC:颈动脉支架置入术的围手术期预后研究

本研究的目的旨在评估一组颈动脉支架置入术(CAS)治疗无症状和症状性颈动脉狭窄的围手术期结局。本研究纳入分析了无症状颈动脉狭窄≥70%和有症状≥50%的年龄≤80岁的颈动脉狭窄患者,主要终点事件是术后30天卒中和死亡的复合事件,次要终点事件是心梗和穿刺相关并发症。最终,共纳入分析了来自98个医学中心的2141名颈动脉狭窄患者,共有2219次CAS操作。患者平均年龄为68岁,男性占65%,白种人占9

NEJM:高出血风险患者PCI方案选择——聚合物药物洗脱支架 vs 无聚合物药物涂层支架

在PCI后1个月接受双重抗血小板治疗的高出血风险患者中,使用聚合物Zotarolimus洗脱支架在安全性和有效性方面与无聚合物药物涂层支架相当

JACC Cardiovasc Interv:陈绍良团队分叉病变处理3年随访结果:治疗无保护左主干分叉病变,DK Crush技术完胜单支架技术

10月14日,JACC子刊刊发南京市第一人民医院陈绍良团队DKCRUSH-V试验3年随访结果,结果显示,对于无保护左主干分叉病变,DK Crush技术完胜单支架技术。

Baidu
map
Baidu
map
Baidu
map